Genome-wide association studies: progress and potential for drug discovery and development.

National Center for Genome Resources, 2935 Rodeo Park Drive East, Santa Fe, New Mexico 87505, USA.
dressNature Reviews Drug Discovery (Impact Factor: 37.23). 04/2008; 7(3):221-30. DOI: 10.1038/nrd2519
Source: PubMed

ABSTRACT Although genetic studies have been critically important for the identification of therapeutic targets in Mendelian disorders, genetic approaches aiming to identify targets for common, complex diseases have traditionally had much more limited success. However, during the past year, a novel genetic approach - genome-wide association (GWA) - has demonstrated its potential to identify common genetic variants associated with complex diseases such as diabetes, inflammatory bowel disease and cancer. Here, we highlight some of these recent successes, and discuss the potential for GWA studies to identify novel therapeutic targets and genetic biomarkers that will be useful for drug discovery, patient selection and stratification in common diseases.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Preclinical Research The progress in genomics and molecular biology during the last decade has led to the insight that complex diseases are caused by defects in many genes and that cellular processes are organized in complex networks. In the search of new drugs, these findings have not yet been fully taken into account. The currently predominating drug discovery approach in pharmaceutical industry is still target-centric, with the goal to optimize compounds toward high affinity and selectivity for a specific target. There is growing evidence that the successful development of effective disease-modifying medications needs a network approach instead. This might also help to reduce the very high failure rate in the current drug development process. This review outlines concepts and applications of network biology and routes toward drugs that are designed to interact with several targets. Obstacles to the implementation of this approach in the pharmaceutical industry are discussed.
    Drug Development Research 08/2014; 75(5):271-282. · 0.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pharmaceutical industry is faced with a range of challenges with the ever-escalating costs of drug development and a drying out of drug pipelines. By harnessing advances in -omics technologies and moving away from the standard, reductionist model of drug discovery, there is significant potential to reduce costs and improve efficacy. Embedding systems biology approaches in drug discovery, which seek to investigate underlying molecular mechanisms of potential drug targets in a network context, will reduce attrition rates by earlier target validation and the introduction of novel targets into the currently stagnant market. Systems biology approaches also have the potential to assist in the design of multidrug treatments and repositioning of existing drugs, while stratifying patients to give a greater personalization of medical treatment. Conflict of interest: The authors have declared no conflicts of interest for this article. For further resources related to this article, please visit the WIREs website.
    Wiley Interdisciplinary Reviews Systems Biology and Medicine 11/2013; · 3.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cu-to-Cu interconnects were achieved by pressureless low temperature sintering of Ag nanoparticles for electronic packaging. Ag nanoparticles could be sintered so long as the chemical bonds by which organic shells connected with Ag nanoparticles were broken with no necessity that organic shells completely decomposed, which provided a way to lower bonding temperature. The pinecone-like recrystallization morphology of sintering Ag nanoparticles was observed by transmission electron microscopy, which resulted from the residuals of organic shells by sintering process. The thermal conductivity of sintered Ag nanoparticles was affected strongly by the recrystallization morphology because of grain boundary scattering effect. The shear strengths of joints reached 17-25 MPa at temperatures ranging from 150 °C to 200 °C.
    Electronic Materials and Packaging (EMAP), 2012 14th International Conference on; 01/2012

Full-text (2 Sources)

Available from
May 29, 2014